Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Light on Molecular Factors Related to SARS-CoV-2 Variants Could Improve COVID-19 Management

By HospiMedica International staff writers
Posted on 10 Feb 2022

Researchers are shedding new light on the molecular factors that give variants of SARS-CoV-2 a competitive edge - essential knowledge that could improve disease management as new variants continue to emerge. More...

A study by researchers at the University of British Columbia (Vancouver, BC Canada) examined the structural and biochemical properties of the Kappa and Delta variants, which co-emerged in India in late 2020. The findings help explain how the Delta variant may have been able to beat out the Kappa variant and become dominant across the globe. For the study, the researchers used cryo-electron microscopy (cryo-EM) to examine the atomic-level structure of the Delta and Kappa viral spike proteins, as well as biochemical studies to assess how strongly the spike protein binds with the ACE2 receptor on human cells.

The researchers found that both variants display evasion from antibodies that target a specific part of the spike protein, known as the N-terminal domain. However, when compared to the Kappa variant and wild-type SARS-CoV-2, the Delta variant spike protein was shown to create stronger bonds with the human ACE2 receptor. Notably, the Kappa variant spike protein displayed an unusual property, where two Kappa spike proteins were able to join together in what’s known as a “stacked head-to-head dimer” - a structure not yet seen in any other SARS-CoV-2 variant. The researchers say it is not clear if this unexpected feature was one of the molecular factors that led to Kappa being outcompeted by the Delta variant.

“We are at a point in the pandemic where new variants continue to emerge and compete with each other. It’s very much survival of the fittest,” said senior author Dr. Sriram Subramaniam, professor in UBC’s faculty of medicine. “Understanding the factors that underpin the ‘fitness’ of each variant will allow us to respond more effectively to emerging threats and better target treatments.”

Related Links:
University of British Columbia 


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.